Small Intestinal Bacterial Overgrowth (SIBO)

Clinical Snapshot

Small intestinal bacterial overgrowth (SIBO) is the presence of an abnormally high bacterial load — historically defined by quantitative culture of jejunal aspirate at greater than 10⁵ colony-forming units (CFU)/mL, a threshold the ACG's 2020 guideline revised downward to 10³ CFU/mL of coliform organisms after studies showed healthy small-bowel fluid typically remains below that lower figure — of colonic-type bacteria within the small intestine, where bacterial density is normally kept low.^[1]

Three host defenses normally keep the small bowel relatively bacteria-sparse: gastric acid, which kills most swallowed organisms before they reach the small intestine; the migrating motor complex (MMC), the cyclical propulsive contraction pattern that sweeps residual bacteria distally into the colon between meals; and the ileocecal valve, which acts as a one-way check valve preventing colonic bacteria from refluxing backward into the small bowel. When gastric acid is suppressed, motility is impaired, or the ileocecal valve is absent or bypassed, bacteria can colonize and persist in the small intestine, ferment dietary carbohydrate prematurely (producing hydrogen and, in a subset of patients, methane), and deconjugate bile acids — the basis of this chapter's symptom picture and, in more advanced cases, its malabsorption findings.^[1]

SIBO is not IBS, even though the two overlap substantially. IBS is a diagnosis of exclusion made on symptom criteria (Rome criteria) in the absence of a demonstrable structural or biochemical cause. SIBO is the opposite in kind: a specific, mechanistically defined, objectively testable, and directly treatable bacterial phenomenon. The genuinely important and still-evolving finding is that a meaningful subset of patients carrying an IBS label — particularly IBS with diarrhea or a mixed pattern — actually have undiagnosed SIBO underlying their symptoms.^[2] This chapter exists to make that distinction explicit and actionable, not to fold the two conditions together — see Assessment & Diagnosis for the evidence and its real limitations.

Recognize the Condition

Typical presentation

Bloating and abdominal distension — often worsening as the day progresses and typically the most prominent complaint — together with excess flatulence, abdominal pain or cramping, nausea, and altered bowel habit. The direction of that bowel-habit change carries real diagnostic weight: hydrogen-predominant (classic) SIBO more often produces watery, non-bloody diarrhea, while methane-predominant disease (intestinal methanogen overgrowth, IMO) more often produces constipation — methane itself has a direct inhibitory effect on small-bowel motility, which is the mechanistic reason for this split and a genuinely useful bedside clue before any breath test is even ordered.^[1]

Malabsorption features in more advanced or longstanding disease

In more chronic or severe cases, bacterial deconjugation of bile acids impairs micelle formation and fat digestion, producing steatorrhea and, over time, deficiency of the fat-soluble vitamins (A, D, E, K). Bacteria also directly consume dietary vitamin B12, while simultaneously synthesizing folate — producing a genuinely distinctive and pharmacist-recognizable laboratory pattern: low or low-normal B12 together with normal or even elevated folate, a combination that should raise SIBO specifically on a differential rather than being read as two unrelated, incidental lab findings. Unintentional weight loss can occur with longstanding, more severe disease, though it is not a typical feature of milder, more common presentations.

Physical examination

Usually unremarkable beyond possible mild distension. A palpable mass, ascites, or focal peritoneal signs are not consistent with uncomplicated SIBO and warrant urgent further assessment rather than being attributed to it (see Red Flags & Refer).

Risk Factors

Motility disorders

Diabetic autonomic neuropathy/gastroparesis — impaired small-bowel motility allows bacteria that would normally be swept distally to persist and multiply.
Hypothyroidism, through its generalized slowing effect on GI transit.
Chronic idiopathic intestinal pseudo-obstruction and other primary dysmotility syndromes.
Parkinson disease, through autonomic/enteric nervous system involvement.
Chronic opioid therapy — a genuinely modifiable, medication-related contributor: opioids slow GI transit and impair the migrating motor complex, and should be considered specifically in a patient on long-term opioid therapy who develops SIBO-compatible symptoms.

Scleroderma (systemic sclerosis) — a specific, high-prevalence association

Systemic sclerosis is one of the strongest single risk factors identified for SIBO: a 2023 systematic review and meta-analysis found a pooled SIBO prevalence of roughly 40% in systemic sclerosis patients, versus a small fraction of that in matched controls, with a pooled odds ratio around 9.6- to 12-fold depending on the specific analysis.^[3] GI dysmotility from smooth-muscle atrophy and fibrosis is the underlying mechanism — SIBO should be actively considered, not treated as a coincidental finding, in any scleroderma patient with bloating, diarrhea, or worsening GI symptoms.

Structural/anatomic abnormalities

Prior GI surgery that alters anatomy — Roux-en-Y gastric bypass and other bariatric procedures, small bowel resection creating a blind loop, and, in particular, ileocecal valve resection (e.g., right hemicolectomy) — removing the valve eliminates the one-way barrier that normally prevents colonic bacteria from refluxing into the small bowel, and is one of the most directly mechanistic, surgically explainable causes of SIBO covered in this chapter.
Small bowel strictures (Crohn disease, radiation enteritis, postoperative adhesions) and small bowel diverticulosis, both of which create areas of relative stasis where bacteria can pool and multiply.

Proton pump inhibitor use — a genuinely important, specific, and modifiable risk factor

Gastric acid is one of the small bowel's primary bacterial defenses, and chronic acid suppression is a real, directly pharmacist-actionable contributor to SIBO risk. A 2013 meta-analysis of 11 studies found PPI use associated with a pooled odds ratio of 2.282 for SIBO (95% CI 1.238-4.205) — but with an important, honestly-reported internal caveat worth passing on rather than smoothing over: the association was strong and clearly significant in the subgroup of studies that used invasive jejunal/duodenal aspirate culture (OR 7.587), but did not reach statistical significance in the subgroup that used glucose hydrogen breath testing (OR 1.93, 95% CI 0.69-5.42) — meaning the true magnitude of PPI-attributable risk is genuinely less certain than the single pooled headline number suggests, and depends partly on which diagnostic method a given study used.^[4] The practical, actionable takeaway for a pharmacist is unchanged despite that nuance: review every chronic PPI for an ongoing, confirmed indication in a patient being worked up for or treated for SIBO (see Choose Initial Treatment and Common Errors to Avoid).

Other predisposing factors

Achlorhydria/hypochlorhydria from other causes — atrophic gastritis, prior vagotomy, or pernicious anemia.
Immunodeficiency — selective IgA deficiency, common variable immunodeficiency.
Chronic pancreatitis/pancreatic exocrine insufficiency, which alters the small-bowel luminal environment.
Cirrhosis, particularly with portal hypertension and associated dysmotility.
Advanced age, reflecting a combination of age-related motility decline, polypharmacy (including chronic PPI and opioid use), and higher rates of the structural/surgical risk factors above.

Red Flags & Refer

The following are not explained by uncomplicated SIBO and should prompt further investigation or referral rather than a presumptive SIBO diagnosis or an empiric breath-test-and-treat approach:

Rectal bleeding or melena.
Significant unintentional weight loss, particularly if out of proportion to reported oral intake.
Fever.
A palpable abdominal mass or ascites on examination.
Signs or symptoms of bowel obstruction — significant nausea/vomiting, obstipation, or severe colicky pain — which can both cause SIBO (via stasis proximal to a stricture) and represent a surgical emergency requiring urgent evaluation rather than outpatient breath testing.
Unexplained iron-deficiency anemia, or laboratory evidence of significant malabsorption (marked hypoalbuminemia, a coagulopathy suggesting vitamin K deficiency) out of proportion to a typical SIBO presentation.
Symptom onset after age 50 without prior evaluation, or a family history of colorectal cancer, inflammatory bowel disease, or celiac disease.
A recent, distinct change in symptom pattern in a patient with previously stable, well-characterized SIBO or IBS.

Any of these findings warrants investigation appropriate to the specific feature (which may include colonoscopy, cross-sectional imaging, or urgent referral) before attributing symptoms to SIBO, and referral to gastroenterology whenever a reasonable, guideline-directed SIBO workup and treatment trial has been ineffective.

Assessment & Diagnosis

Why SIBO is not simply "IBS with a different name"

	Irritable bowel syndrome (IBS)	Small intestinal bacterial overgrowth (SIBO)
Diagnostic basis	Symptom-based criteria (Rome), a positive clinical diagnosis after excluding a limited set of alarm-feature-driven alternatives	A specific, mechanistically defined bacterial phenomenon with an objective, testable basis (breath testing or jejunal aspirate culture)
Confirmatory test	None — no biomarker exists for IBS itself	Lactulose or glucose hydrogen/methane breath test (practical clinical standard), or quantitative jejunal aspirate culture (invasive reference standard, rarely used clinically)
Core treatment	Multimodal — diet, fibre, gut-directed psychotherapy, and symptom-targeted drug therapy matched to bowel-habit subtype	Antibiotic-directed bacterial eradication (rifaximin ± neomycin/metronidazole), plus correction of the underlying predisposing cause
Relapse driver	Not applicable in the same sense — IBS is a chronic, relapsing-remitting condition by definition	Recurrence is common specifically when the underlying predisposing cause (motility disorder, anatomic alteration, unaddressed chronic PPI use) is not identified and addressed alongside antibiotic therapy

The genuine, evidence-hedged overlap between the two

A 2020 systematic review and meta-analysis of case-control studies found SIBO detected significantly more often in patients meeting IBS criteria than in controls — but the pooled estimate varied enormously depending on which diagnostic method the underlying studies used (jejunal aspirate culture versus glucose versus lactulose breath testing), and the authors themselves flagged marked between-study heterogeneity and a real risk of publication bias favouring positive associations.^[2] The honest, clinically useful conclusion from this body of evidence is not "most IBS is actually SIBO" — it is that a real, clinically meaningful minority of patients carrying an IBS label, particularly those with a diarrhea-predominant or mixed pattern, have a genuinely treatable bacterial contributor that is worth actively testing for, especially when standard IBS-directed therapy has been tried and has failed, or when a predisposing condition from Risk Factors is present.

Breath testing — the practical noninvasive diagnostic standard

Quantitative culture of jejunal aspirate (≥10³ CFU/mL of coliform organisms under the revised 2020 threshold) is the technical reference standard, but it requires upper endoscopy, is not widely available, and carries a real risk of contamination from oropharyngeal flora during passage of the aspiration catheter — for these practical reasons, hydrogen/methane breath testing, following the North American Consensus (NAC) technique and interpretation criteria, is the diagnostic approach actually used in clinical practice and the one this guideline endorses as the practical standard.^[1]^[5]

Test	How it works	Positivity criteria (NAC 2017)	Key interpretation caveat
Glucose hydrogen/methane breath test	75 g glucose is fully absorbed in the proximal small bowel under normal conditions, so any fermentation gas detected implies bacteria are present proximally, before absorption is complete	Hydrogen rise ≥20 ppm above baseline within 90 minutes	More specific for proximal SIBO, but can miss overgrowth confined to the distal small bowel, since glucose may already be fully absorbed before reaching it
Lactulose hydrogen/methane breath test	10 g lactulose is not absorbed anywhere in the small bowel, so it transits the entire small intestine before reaching the colon	Hydrogen rise ≥20 ppm above baseline within 90 minutes (before expected colonic arrival)	Tests the whole small bowel, but rapid orocecal transit (common in diarrhea-predominant states) can produce a falsely early "colonic" gas peak that mimics a true SIBO pattern — a genuine, guideline-recognized limitation that reduces this test's specificity relative to the glucose test
Methane, either substrate	Produced by methanogenic archaea (not bacteria in the strict sense), which consume hydrogen as a substrate	Methane ≥10 ppm at any point during the test	A positive methane result defines intestinal methanogen overgrowth (IMO) regardless of the hydrogen result, and changes antibiotic selection — see below

An emerging third gas, hydrogen sulfide, is increasingly recognized as a contributor to some breath-test-negative, symptomatic patients and is now measurable with newer commercial three-gas breath tests, but validated positivity thresholds for hydrogen sulfide are not yet incorporated into the North American Consensus criteria above — treat this as a genuinely evolving area rather than part of the current diagnostic standard.^[5]

Methane-positive results are not "SIBO with an extra gas" — they define a different entity (IMO)

Methanogens are archaea, biologically distinct from the bacteria that drive classic hydrogen-predominant SIBO, and current terminology increasingly separates intestinal methanogen overgrowth (IMO) as its own entity rather than a subtype of "SIBO" in the strict sense.^[1] This distinction is not academic: methane slows small-bowel transit and is mechanistically linked to constipation rather than diarrhea, and — critically for treatment selection — rifaximin alone is meaningfully less effective against methanogens than against the bacteria of classic SIBO, which is why methane-positive results change the antibiotic regimen (see Choose Initial Treatment).^[6]

An empiric antibiotic trial without formal testing

In a patient with a high pretest probability — most often a clear predisposing cause already identified (a documented motility disorder, surgically altered anatomy with an absent ileocecal valve) — and no access to breath testing, an empiric antibiotic trial is a reasonable, guideline-supported option rather than an absolute requirement to formally test first.^[1]

Treatment Targets

Achieve meaningful symptom relief — bloating, gas, pain, and bowel-habit normalization — as the primary, patient-centred goal; breath-test normalization is a reasonable secondary marker but not itself required to call treatment successful.
Select antibiotic therapy matched to the actual gas pattern (hydrogen-predominant versus methane-positive/IMO) rather than a single default regimen for every patient.
Identify and address the underlying predisposing cause identified in Risk Factors — this is not an optional add-on but a genuinely essential step for preventing relapse, since antibiotics alone, without addressing the driver, carry a real and well-recognized high relapse rate.
Correct any identified nutritional deficiency (vitamin B12, fat-soluble vitamins) alongside bacterial eradication.
Avoid unnecessary, repeated, broad-spectrum systemic antibiotic exposure — favour gut-selective, minimally absorbed agents wherever the clinical picture allows.

Choose Initial Treatment

Direct treatment rule

Hydrogen-predominant (classic) SIBO

1st line rifaximin 550 mg PO three times daily for 14 days — the only agent with consistent, guideline-preferred trial evidence for SIBO, chosen specifically for its minimal (well under 1%) systemic absorption and gut-selective mechanism.^[1]

Methane-predominant SIBO / intestinal methanogen overgrowth (IMO)

1st line for a positive methane result rifaximin plus neomycin combination therapy, not rifaximin alone — the pivotal trial found this combination eradicated methane and produced clinical response in a substantially higher proportion of methane-positive patients than either drug alone.^[6]

Alternative combination rifaximin plus metronidazole, a reasonable substitution when avoiding an aminoglycoside is preferred — for example, prior neomycin-related ototoxicity concern, or a patient anticipated to need multiple retreatment courses over time, given neomycin's small but real cumulative ototoxicity/nephrotoxicity risk with repeated dosing.

Every patient — before or alongside antibiotic therapy

Essential, not optional systematically review the patient's predisposing-cause profile from Risk Factors and act on whatever is modifiable: confirm an ongoing indication for any chronic PPI and deprescribe or step down where feasible, refer for evaluation/management of an underlying motility disorder, and involve the surgical/GI team where an anatomic driver (e.g., an absent ileocecal valve, a stricture) could realistically be addressed. Antibiotics without this step lead to a genuinely high relapse rate — treating the bacterial overgrowth without addressing why it developed is treating the consequence, not the cause.^[1]

When antibiotics are not tolerated, not accessible, or declined

Alternative a 14- to 21-day elemental diet trial — an exclusively absorbable, pre-digested liquid formula intended to starve small-bowel bacteria of fermentable substrate while still nourishing the patient — has real supporting evidence from its original trial (roughly 80% lactulose-breath-test normalization at 14 days, rising to roughly 85% by 21 days in patients who continued), though this is a single, small, unblinded trial, and poor palatability plus cost/access are genuine practical barriers to recommend honestly rather than minimize.^[7]

Non-Pharmacologic Treatment

Identifying and addressing the underlying predisposing cause — the step most likely to prevent relapse

This is the single most important nonpharmacologic intervention in this chapter, not a secondary consideration after antibiotics. Work through the Risk Factors list with the patient's own history in mind: is there a chronic PPI continued without a confirmed ongoing indication? A diagnosed or suspected motility disorder (diabetes, hypothyroidism, scleroderma) that is itself undertreated? A surgical history that removed the ileocecal valve or created a blind loop? Addressing what is actually modifiable is what separates a durable response from a pattern of repeated retreatment.^[1]

Dietary approaches — genuinely supportive, not primary therapy

Low-FODMAP diet: restricting fermentable oligo-, di-, and monosaccharides and polyols reduces the substrate available for bacterial fermentation and is a reasonable adjunct for symptom control, best used for a defined trial period with structured reintroduction rather than indefinitely. The evidence specifically in SIBO (as opposed to its considerably better-established role in IBS) remains limited, and at least one recent narrative review raises a genuine, appropriately hedged theoretical concern: restricting fermentable substrate too aggressively or for too long could plausibly deepen an existing dysbiosis rather than correct it, which is a real reason to favour dietitian involvement and a bounded trial over an open-ended restrictive diet.^[8]
Elemental diet: covered above as an antibiotic alternative; the same practical and evidence-strength caveats apply if used as an adjunct alongside, rather than instead of, antibiotic therapy.^[7]
Smaller, more frequent meals and allowing genuine fasting intervals between meals support normal migrating motor complex activity, which is itself one of the small bowel's natural anti-bacterial-overgrowth defenses; near-constant grazing can theoretically blunt this cyclical motor pattern.

Nutritional repletion

Replace vitamin B12 and fat-soluble vitamins (A, D, E, K) where deficiency is confirmed, particularly in a patient with a longer symptom duration or evidence of steatorrhea — correcting bacterial overgrowth does not instantly reverse an established deficiency, and repletion should proceed in parallel with, not only after, antibiotic-directed treatment.

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Rifaximin Preferred	1st-line, hydrogen-predominant (classic) SIBO	550 mg PO three times daily for 14 days	Diarrhea (paradoxical), nausea; minimal systemic absorption	Gut-selective, well under 1% systemic absorption gives a favourable safety profile relative to systemic antibiotics; may be retreated if symptoms recur after an initial response.
Rifaximin + neomycin Preferred	1st-line, methane-predominant SIBO / intestinal methanogen overgrowth (IMO)	Combo: rifaximin 550 mg PO three times daily + neomycin 500 mg PO twice daily for 14 days	Neomycin: rare ototoxicity/nephrotoxicity, mainly a concern with prolonged or repeated courses	Outperforms either agent alone for methane eradication in the pivotal trial; use some caution with repeated neomycin courses given cumulative aminoglycoside exposure risk over time.
Rifaximin + metronidazole Alternative	Methane-predominant SIBO/IMO, when avoiding an aminoglycoside is preferred	Combo: rifaximin 550 mg PO three times daily + metronidazole 250 mg PO three times daily for 14 days	Metronidazole: metallic taste, GI upset, peripheral neuropathy with prolonged/repeated use, disulfiram-like reaction with alcohol	A reasonable substitute for the neomycin combination when prior ototoxicity, renal impairment, or anticipated repeated retreatment make an aminoglycoside less appealing; metronidazole is systemically absorbed, unlike rifaximin and neomycin.
Loperamide Alternative	Symptomatic adjunct for diarrhea in hydrogen-predominant SIBO	4 mg PO after the first loose stool, then 2 mg after each subsequent loose stool, maximum 16 mg/24h	Constipation; caution in methane-predominant/IMO, where constipation may already be the dominant problem	Controls stool consistency/urgency only — does not treat the underlying bacterial overgrowth and should not substitute for antibiotic-directed therapy.
Erythromycin (low-dose) Special situation	Prokinetic maintenance to reduce relapse risk once eradication is achieved, specifically in a patient with an underlying, not-fully-correctable motility disorder	50 mg PO at bedtime — well below antibacterial dosing	QT prolongation at higher doses, GI cramping; motilin-receptor tachyphylaxis can blunt effect with continued use	Evidence limited to small trials; reserve for a genuine, identified motility driver rather than routine post-treatment use in every patient.
Prucalopride Special situation	Alternative prokinetic maintenance option, particularly with a constipation-predominant/IMO history	2 mg PO once daily (1 mg once daily if age 65+, creatinine clearance 30 mL/min or less, or severe hepatic impairment)	Nausea, diarrhea, abdominal pain, headache	Mechanistically reasonable for relapse prevention in a documented motility disorder; SIBO-specific trial data are limited.

Special Populations

Pregnancy and breastfeeding

SIBO itself is not a contraindication to pregnancy. Rifaximin's minimal systemic absorption is reassuring in principle, but dedicated pregnancy/lactation safety data are limited — use only when benefit clearly outweighs uncertainty, and involve the patient's obstetric care team in the decision. Metronidazole is generally considered compatible with pregnancy beyond the first trimester per standard obstetric guidance, and small amounts transfer into breast milk; discuss with the prescriber and obstetric/lactation team rather than defaulting to it reflexively. Neomycin has minimal absorption at gut-directed doses; formal pregnancy-specific SIBO trial data do not exist. Nondrug measures (meal spacing, addressing a modifiable predisposing cause) remain first-line wherever feasible.

Older adults

This is genuinely a high-risk population for SIBO given the cumulative burden of age-related motility decline, chronic PPI use, and prior GI surgery. Malabsorption findings (unintentional weight loss, B12 deficiency, fat-soluble vitamin deficiency) carry real functional and fall-risk consequences in frail older adults and should be actively screened for rather than attributed to "normal aging." Review the full medication list for both PPI and opioid contributors specifically in this group. Reduce the prucalopride starting dose to 1 mg once daily at age 65 and older.

Patients who cannot have the predisposing cause corrected

Not every driver is reversible — a permanently altered surgical anatomy, an absent ileocecal valve, or an irreversible motility disorder cannot simply be "fixed." In these patients, expect a genuinely higher relapse rate despite adequate antibiotic therapy, and consider low-dose prokinetic maintenance (erythromycin or prucalopride) as a reasonable, evidence-limited option to reduce relapse frequency rather than accepting repeated, closely spaced antibiotic courses as the only option.

Scleroderma/systemic sclerosis patients

Given the roughly 40% prevalence and strongly elevated odds ratio in this population, maintain a low threshold to test or empirically treat for SIBO in a scleroderma patient with GI symptoms, and anticipate that recurrence is likely given the underlying, generally non-reversible dysmotility — prokinetic maintenance and periodic retreatment, rather than a single curative course, is the realistic long-term management framework in this group.^[3]

Renal and hepatic impairment

Neomycin requires caution in renal impairment given its aminoglycoside class, even at gut-directed doses with minimal systemic absorption. Metronidazole requires dose reduction in severe hepatic impairment given reduced hepatic clearance. Prucalopride requires the reduced 1 mg dose in severe renal impairment (creatinine clearance 30 mL/min or less) and severe hepatic impairment. Rifaximin needs no adjustment in mild-to-moderate hepatic impairment but should be used cautiously in severe (Child-Pugh class C) impairment given increased systemic absorption in that setting.

Monitoring & Follow-Up

Reassess symptom response at the end of the antibiotic course (roughly 2 weeks) rather than leaving follow-up open-ended — genuine benefit is usually apparent by then. Repeat breath testing to confirm normalization is reasonable but not mandatory if the patient is clinically well, since symptom control, not a specific breath-test number, is the primary treatment target.^[1] Reassess and correct any identified nutritional deficiency (B12, fat-soluble vitamins) on an ongoing basis, since repletion can take considerably longer than symptom resolution. At every follow-up, specifically confirm that the predisposing-cause conversation from Choose Initial Treatment actually happened and was actioned — was the PPI indication genuinely reviewed, was a referral for the underlying motility disorder actually made — rather than assuming a single mention at diagnosis was sufficient. Re-screen for new alarm features at any point symptoms change in character, since a stable, previously well-characterized SIBO pattern can still be interrupted by a new, unrelated diagnosis.

Treatment Failure / Next Step

Confirm the diagnosis and the treatment actually matched the gas pattern found on testing — a methane-positive result treated with rifaximin alone is a common, specifically avoidable cause of apparent treatment failure.
Confirm adherence and correct completion of the full antibiotic course before concluding it failed.
Reconfirm that the predisposing cause was actually identified and addressed, not just discussed — an unaddressed chronic PPI, an unreferred motility disorder, or an uncorrected anatomic driver is the single most common reason for early relapse after an otherwise adequate antibiotic course.
If hydrogen-predominant therapy (rifaximin alone) failed, reconsider whether methane or another gas pattern was actually present, and retest if this was not clearly characterized initially.
Retreat with the same regimen if there was an initial response followed by relapse, or switch to the alternate methane-directed combination (rifaximin plus metronidazole in place of rifaximin plus neomycin, or vice versa) if the first combination was inadequate.
Consider low-dose prokinetic maintenance (erythromycin or prucalopride) in a patient with a persistent, not-fully-correctable motility driver and a pattern of frequent relapse.
Reconsider the diagnosis itself in a patient who has genuinely failed guideline-directed, gas-pattern-matched antibiotic therapy with the predisposing cause addressed — screen for celiac disease, inflammatory bowel disease, or another overlapping condition rather than escalating antibiotic courses indefinitely, and refer to gastroenterology.

Common Errors to Avoid

Treating every "IBS-like" presentation as either purely IBS or purely SIBO instead of considering both — particularly in diarrhea-predominant or treatment-refractory presentations, where the evidence for a meaningful SIBO subset is genuine, if imperfect.^[2]
Using rifaximin alone for a methane-positive result — methanogens respond meaningfully less well to rifaximin monotherapy, and this specific mismatch is a common, avoidable cause of treatment failure.^[6]
Treating antibiotics as a complete, standalone solution without identifying and addressing the underlying predisposing cause — this is the single most common driver of relapse covered in this chapter.^[1]
Continuing a chronic PPI indefinitely in a SIBO patient without ever reconfirming the original indication still applies — a broadly under-deprescribed pattern that is directly, specifically relevant here.^[4]
Missing the low-B12/normal-or-high-folate laboratory pattern as a clue toward SIBO, or attributing it to two unrelated incidental findings.
Presenting the low-FODMAP diet or the elemental diet as an established, primary cure for SIBO rather than an adjunct or antibiotic-alternative with real but genuinely limited supporting evidence.^[8]^[7]
Assuming a positive breath test always requires exhaustive further workup before treatment can start, rather than proceeding directly to gas-pattern-matched antibiotic therapy in a patient without alarm features.
Overlooking scleroderma, prior GI surgery removing the ileocecal valve, or chronic opioid therapy as specific, worth-asking-about predisposing causes.

Clinical Decision Algorithm

Algorithm A — Diagnostic pathway

Bloating, gas, abdominal pain, or altered bowel habit — especially with a predisposing condition present (motility disorder, prior GI surgery, chronic PPI use, scleroderma) or symptoms refractory to standard IBS-directed therapy

Screen for red flags

A red flag is present

Do not presume SIBO — investigate per the specific feature (imaging, colonoscopy, urgent referral) before considering breath testing

No red flags; predisposing condition present, or IBS-directed therapy already tried and failed

Lactulose or glucose hydrogen/methane breath test, per North American Consensus technique^[5]

Hydrogen rises ≥20 ppm above baseline within 90 minutes

Hydrogen-predominant (classic) SIBO confirmed

Methane ≥10 ppm at any point, either substrate

Methane-predominant SIBO / intestinal methanogen overgrowth (IMO) confirmed — treat as IMO regardless of the hydrogen result^[5]

Breath testing unavailable, but high pretest probability (clear predisposing cause identified)

Consider an empiric antibiotic trial without formal testing^[1]

Algorithm B — Treatment ladder

Confirmed or empirically presumed SIBO

Hydrogen-predominant

Rifaximin 550 mg PO three times daily for 14 days

Methane-predominant / IMO

Rifaximin plus neomycin (or rifaximin plus metronidazole) combination for 14 days^[6]

Antibiotics not tolerated, not accessible, or declined

14- to 21-day elemental diet trial^[7]

Alongside antibiotic/diet therapy: review and act on the underlying predisposing cause — do not defer this step until after treatment

Symptom response

Continue to Algorithm C — sustaining response and preventing relapse

Inadequate response

Reassess: confirm the antibiotic regimen actually matched the gas pattern found, confirm adherence/completion, and reconsider the diagnosis before escalating further

Algorithm C — Preventing relapse

Symptom response achieved after antibiotic-directed (or elemental diet) therapy

The predisposing cause is correctable (unnecessary chronic PPI, undertreated motility disorder, addressable anatomic driver)

Address it directly — meaningfully reduces relapse risk beyond antibiotics alone

The predisposing cause is not correctable (permanent anatomic alteration, irreversible motility disorder, e.g. scleroderma)

Consider low-dose prokinetic maintenance — erythromycin or prucalopride — to reduce relapse frequency^[1]

Relapse occurs

Retreat with the same or the alternate gas-pattern-matched regimen; reconfirm the gas pattern with repeat breath testing where feasible rather than assuming it is unchanged

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

First-Line — Hydrogen-Predominant (Classic) SIBO

Rifaximin is the only agent with consistent, guideline-preferred trial evidence for SIBO, chosen specifically for its minimal systemic absorption.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Rifaximin	Adults: 550 mg PO three times daily for 14 days	Diarrhea (paradoxical), nausea	Cyclosporine increases rifaximin levels via P-glycoprotein inhibition; may reduce the effectiveness of sodium-picosulfate-containing bowel preparations; may reduce warfarin effectiveness — monitor INR	Well under 1% systemic absorption; acts locally in the gut. May be safely retreated if symptoms recur after an initial response.^[1]

First-Line — Methane-Predominant SIBO / Intestinal Methanogen Overgrowth (IMO)

Rifaximin monotherapy is meaningfully less effective against methanogens than against the bacteria of classic SIBO — combination therapy is the guideline-preferred approach for a positive methane result.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Rifaximin + neomycin	Adults: Rifaximin 550 mg PO three times daily plus neomycin 500 mg PO twice daily, both for 14 days	Rifaximin: diarrhea (paradoxical), nausea. Neomycin: rare ototoxicity/nephrotoxicity, mainly with prolonged or repeated courses	As for rifaximin alone; neomycin has minimal additional systemic interaction potential at gut-directed doses	The pivotal trial found this combination eradicated methane and produced clinical response in substantially more methane-positive patients than either agent alone. No standalone oral neomycin monograph exists on this platform (only topical/ophthalmic combination products), so neomycin appears as plain text.^[6]
Rifaximin + metronidazole	Adults: Rifaximin 550 mg PO three times daily plus metronidazole 250 mg PO three times daily, both for 14 days	Rifaximin: diarrhea (paradoxical), nausea. Metronidazole: metallic taste, GI upset, peripheral neuropathy with prolonged/repeated use, disulfiram-like reaction with alcohol	Metronidazole: avoid alcohol during and for 48-72 hours after treatment; may potentiate warfarin — monitor INR; avoid with disulfiram	A reasonable alternative combination when avoiding an aminoglycoside is preferred (prior ototoxicity concern, anticipated repeated retreatment); unlike the rifaximin-neomycin pairing, metronidazole is systemically absorbed.

Symptomatic Adjunct

Controls stool consistency/urgency only — does not treat the underlying bacterial overgrowth and should not substitute for antibiotic-directed therapy.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Loperamide	Adults: 4 mg PO after the first loose stool, then 2 mg after each subsequent loose stool, maximum 16 mg/24h	Constipation; caution in methane-predominant/IMO where constipation may already be the dominant problem	None significant at standard doses	Use PRN for diarrhea associated with hydrogen-predominant SIBO; avoid routine use in a constipation-predominant/IMO pattern.

Prokinetic Maintenance — Relapse Prevention

Reserve for a patient with a genuine, not-fully-correctable underlying motility driver after eradication is achieved, rather than routine post-treatment use in every patient. Evidence for both agents in this specific role is limited to small trials.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Erythromycin (low-dose)	Adults: 50 mg PO at bedtime	QT prolongation at higher doses, GI cramping; motilin-receptor tachyphylaxis can blunt effect with continued use	Numerous CYP3A4-mediated interactions at antibacterial doses; lower risk but not absent at this low prokinetic dose — review the full medication list	Dosed well below antibacterial range specifically for its prokinetic, not antibacterial, effect.^[1]
Prucalopride	Adults: 2 mg PO once daily	Nausea, diarrhea, abdominal pain, headache	Minimal CYP-mediated interaction potential	Reduce to 1 mg once daily if age 65 or older, creatinine clearance 30 mL/min or less, or severe hepatic impairment.

Chronic Acid Suppression — Review for Ongoing Indication

Gastric acid is a primary small-bowel bacterial defense; chronic PPI use is a genuinely important, modifiable SIBO risk factor. None of these are contraindicated outright, but each deserves a specific ongoing-indication review at SIBO diagnosis — see Risk Factors and Choose Initial Treatment. Pooled odds ratio 2.282 (95% CI 1.238-4.205) from a 2013 meta-analysis, with a caveat worth passing on: the association was significant in culture-based studies (OR 7.587) but not in glucose-breath-test-based studies (OR 1.93) within that same pooled analysis.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Omeprazole	Review: Confirm an ongoing indication exists; consider dose reduction or discontinuation	As per product monograph; the association with SIBO is the reason for review here, not a direct adverse effect of ordinary use	Standard PPI interaction profile (reduced absorption of drugs requiring gastric acidity)	Confirm an ongoing indication exists before continuing; consider stepping down to the lowest effective dose or an H2-receptor antagonist where clinically appropriate.^[4]
Lansoprazole	Review: Confirm an ongoing indication exists; consider dose reduction or discontinuation	As per product monograph	Standard PPI interaction profile	Same class-wide SIBO association as other PPIs; review ongoing indication.^[4]
Pantoprazole	Review: Confirm an ongoing indication exists; consider dose reduction or discontinuation	As per product monograph	Standard PPI interaction profile	Same class-wide SIBO association as other PPIs; review ongoing indication.^[4]
Esomeprazole	Review: Confirm an ongoing indication exists; consider dose reduction or discontinuation	As per product monograph	Standard PPI interaction profile	Same class-wide SIBO association as other PPIs; review ongoing indication.^[4]
Rabeprazole	Review: Confirm an ongoing indication exists; consider dose reduction or discontinuation	As per product monograph	Standard PPI interaction profile	Same class-wide SIBO association as other PPIs; review ongoing indication.^[4]

References

ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth — American Journal of Gastroenterology, American College of Gastroenterology (Pimentel M, Saad RJ, Long MD, Rao SSC). Am J Gastroenterol 2020;115(2):165-178
Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: A Systematic Review and Meta-analysis of Case-Control Studies — American Journal of Gastroenterology (Shah A, Talley NJ, Jones M, Kendall BJ, Koloski N, Walker MM, Morrison M, Holtmann GJ). Am J Gastroenterol 2020;115(2):190-201
Small Intestinal Bacterial Overgrowth Complicating Gastrointestinal Manifestations of Systemic Sclerosis: A Systematic Review and Meta-analysis — Journal of Neurogastroenterology and Motility (Shah A, Pakeerathan V, Jones MP, Kashyap PC, Virgo K, Fairlie T, Morrison M, Ghoshal UC, Holtmann GJ). J Neurogastroenterol Motil 2023;29(2):132-144
Proton Pump Inhibitor Use and the Risk of Small Intestinal Bacterial Overgrowth: A Meta-analysis — Clinical Gastroenterology and Hepatology (Lo WK, Chan WW). Clin Gastroenterol Hepatol 2013;11(5):483-490
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus — American Journal of Gastroenterology (Rezaie A, Buresi M, Lembo A, et al.). Am J Gastroenterol 2017;112(5):775-784
A Combination of Rifaximin and Neomycin Is Most Effective in Treating Irritable Bowel Syndrome Patients With Methane on Lactulose Breath Test — Journal of Clinical Gastroenterology (Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M). J Clin Gastroenterol 2010;44(8):547-550
A 14-Day Elemental Diet Is Highly Effective in Normalizing the Lactulose Breath Test — Digestive Diseases and Sciences (Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S). Dig Dis Sci 2004;49(1):73-77
Nutritional Approach to Small Intestinal Bacterial Overgrowth: A Narrative Review — Nutrients (Velasco-Aburto S, Llama-Palacios A, Sánchez MC, Ciudad MJ, Collado L). Nutrients 2025;17(9):1410

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.